Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has shared an update. Polestar Automotive Holding UK PLC, the Swedish electri...

Polestar Posts Record Q1 2026 Retail Sales and Rapid Network Expansion

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NovaBridge Biosciences (NBP) and Sanofi (SNYNF) with...

Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NBP) and Sanofi (OtherSNYNF)

Synergy Chc Corp (($SNYR)) has held its Q4 earnings call. Read on for the main highlights of the call. Synergy CHC’s latest earnings call painted a...

Synergy CHC’s Earnings Call Balances Pain And Promise

Anthropic, the artificial intelligence (AI) firm behind Claude, has just bought a small biotech startup called Coefficient Bio for about $400 milli...

Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio

Synergy CHC ( ($SNYR) ) has released a notification of late filing. Synergy CHC Corp. has filed a Form 12b-25 to notify investors of a delay in sub...

Synergy CHC delays annual Form 10-K filing

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) has provided an update. Sany Heavy Equipment International Holdings has approved a ne...

Sany Heavy Equipment Grants Over 18 Million Restricted Shares Under Incentive Scheme

Sanofi ( ($SNY) ) has issued an update. In March 2026, Sanofi reported a series of regulatory and clinical milestones that deepen its immunology fo...

Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) has shared an announcement. Sany Heavy Equipment International reported a robust set ...

Sany Heavy Equipment Profit Jumps 62% as Revenue Climbs, Dividend Raised

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) has issued an announcement. Sany Heavy Equipment International Holdings Company Limit...

Sany Heavy Equipment Proposes HKD 0.35 Final Dividend for 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNY), Milestone Pharmaceuticals (MIST) and...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) just unveiled an announcement. On 31 March 2026, Polestar said Snita Holding ...

Polestar Reshapes Capital Structure and Concentrates Polestar 3 Production in U.S.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY), Sanofi (SNYNF) and Johnson & Johnso...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Sanofi (OtherSNYNF) and Johnson & Johnson (JNJ)

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi, with a price target of €95.00. Vosser covers the He...

J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)

Kepler Capital analyst Jose Porta maintained a Sell rating on Naturgy Energy Group, S.A. on March 27 and set a price target of €24.30. Porta covers...

Naturgy Energy Group, S.A. (0NPV) Gets a Sell from Kepler Capital

Naturgy Energy Group SA ( ($GASNY) ) has provided an announcement. Naturgy Energy Group S.A.’s Ordinary General Shareholders’ Meeting approved the ...

Naturgy Shareholders Approve 2025 Accounts, Governance Measures and Dividend

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF) and LENZ Therapeutics (LENZ). Sanofi (SNYNF) In a ...

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and LENZ Therapeutics (LENZ)

Sanofi ( ($SNY) ) has issued an update. On March 18, 2026, Sanofi announced that the U.S. Food and Drug Administration granted Breakthrough Therapy...

Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on Sany Heavy Equipment International Holdings Co (SNYYF) and ...

Analysts’ Opinions Are Mixed on These Industrial Goods Stocks: Sany Heavy Equipment International Holdings Co (OtherSNYYF) and Hillman Solutions (HLMN)

Barclays analyst Peter Crampton maintained a Hold rating on Naturgy Energy Group, S.A. on March 20 and set a price target of €28.00. The company’s ...

Barclays Remains a Hold on Naturgy Energy Group, S.A. (0NPV)

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) has issued an update. Sany Heavy Equipment International said it expects unaudited ne...

Sany Heavy Equipment forecasts up to 73% surge in 2025 profit on lower impairments and lithium growth

In a report released today, Luisa Hector from Berenberg Bank maintained a Buy rating on Sanofi, with a price target of €105.00. Hector covers the H...

Sanofi (SNYNF) Gets a Buy from Berenberg Bank

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medline (MDLN), Protagonist Therapeutics (PTGX) and ...

Analysts Are Bullish on These Healthcare Stocks: Medline (MDLN), Protagonist Therapeutics (PTGX)

Sanofi ($SNYNF) announced an update on their ongoing clinical study. The Phase 2b study titled “A Randomized, Double-blind, Placebo-controlled, Par...

Sanofi’s Lunsekimig Asthma Study Completion: What Investors Should Watch Next

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) just unveiled an update. On 16 March 2026, Polestar announced it had secured ...

Polestar Raises USD 300 Million in New Equity Financing, Completing USD 1 Billion Capital Push

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi’s new study, “Long-Term Outcomes of Participants Treated With Teplizum...

Sanofi Targets Real-World Teplizumab Data in Type 1 Diabetes: What Investors Should Watch

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. The Impact of Dupilumab Treatment on Anxie...

Current Quarter	$1.06	Next Quarter	$1.26
Current Year	$4.97	Next Year	$5.18
QoQ Growth	+18.9%	YoY Growth	+4.2%
3Y EPS CAGR	+0.0%	Target Price	$57.87
Consensus	Buy	Upside	+22.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$47.14	0.00%	4.51M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$47.14	0%	4.51M
3
4
5
6

SNY

SNY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sanofi Data in Excel

Get Sanofi Data in Excel